QUIT ACHIEVE LIFE SCIENCES, INC.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 949858 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-113.4%
TTM EPS YoY-4.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-104.2%
ROA-86.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets12.4%
Debt / equity0.00x
Current ratio10.49x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.39x
Accruals ratio-52.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | — | $22.82M | $15.81M | $30.08M | $23.97M |
| SG&A expense | — | $16.25M | $11.44M | $10.72M | $9.13M |
| Interest expense | $819,000 | $2.18M | $2.85M | $1.79M | — |
| Pretax income | -$54.65M | -$39.83M | -$29.82M | -$42.35M | -$33.15M |
| Net income | -$54.65M | -$39.83M | -$29.82M | -$42.35M | -$33.15M |
| EPS (basic) | -1.25 | -1.24 | -1.50 | -4.00 | -4.08 |
| EPS (diluted) | -1.25 | -1.24 | -1.50 | -4.00 | -4.08 |
| Weighted avg. shares (diluted) | 43.59M | 32.07M | 19.83M | 10.59M | 8.12M |
| Balance sheet | |||||
| Cash & equivalents | $20.93M | $12.75M | $15.55M | $24.77M | $43.02M |
| Short-term investments | $15.47M | $21.61M | — | — | — |
| Current assets | $39.89M | $36.47M | $16.98M | $27.33M | $44.59M |
| PP&E, net | $3,000 | $8,000 | $13,000 | $4,000 | $15,000 |
| Goodwill | $1.03M | $1.03M | $1.03M | $1.03M | $1.03M |
| Intangibles | $751,000 | $974,000 | $1.20M | $1.42M | $1.64M |
| Total assets | $41.79M | $38.63M | $19.37M | $29.97M | $47.52M |
| Current liabilities | $9.08M | $6.68M | $20.81M | $21.60M | $4.55M |
| Total liabilities | $20.27M | $17.73M | $20.82M | $21.67M | $19.47M |
| Shareholders' equity | $21.52M | $20.90M | -$1.45M | $8.30M | $28.04M |
| Shares outstanding | 53.23M | 34.69M | 21.17M | 17.90M | 9.45M |
| Cash flow statement | |||||
| Operating cash flow | -$49.47M | -$29.77M | -$24.48M | -$37.57M | -$29.44M |
| Capital expenditure | $3,000 | — | $21,000 | — | — |
| Free cash flow | -$49.47M | — | -$24.50M | — | — |
| Investing cash flow | $6.11M | -$21.58M | -$21,000 | — | — |
| Financing cash flow | $51.53M | $48.53M | $15.28M | $19.32M | $36.61M |
| Depreciation & amortization | $228,000 | $229,000 | $228,000 | $236,000 | $250,000 |
| Stock-based compensation | $8.76M | $5.33M | $3.44M | $3.27M | $2.19M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.